Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.
about
Duration of adjuvant chemotherapy for patients with non-metastatic colorectal cancerRETRACTED: A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunitiesCurrent adjuvant treatment modalities for gastric cancer: From history to the futureThe IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 montOptimizing adjuvant therapy and survivorship care of stage III colon cancer.Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised coImpact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials.Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data setEvaluation of biodistribution and safety of adenovirus vector containing MDR1 in miceColorectal cancer treatmentANXA9 gene expression in colorectal cancer: A novel marker for prognosis.Adjuvant therapy for resected high-risk colon cancer: Current standards and controversiesCapecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy.Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database.Cancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients.Saudi Oncology Society clinical management guideline series. Gastric cancer 2014.Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery.Prognostic relevance of LGALS3BP in human colorectal carcinoma.Association Between Time (Initiation and Length) and Oncological Outcomes for the Patients with Colon Cancer Treated with Adjuvant ChemotherapyGermline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer.High Risk Stage 2 and Stage 3 Colon Cancer, Predictors of Recurrence and Effect of Adjuvant Therapy in a Nonselected Population.Prognostic value of colorectal cancer biomarkers.Accomplishments in 2007 in the adjuvant treatment of colorectal cancerAdjuvant FOLFOX treatment for stage III colon cancer: how many cycles are enough?Treatment in advanced colorectal cancer: what, when and how?Accomplishments in 2008 in the adjuvant treatment of colon cancer.Expression of aquaporin-1 is a poor prognostic factor for stage II and III colon cancer.Adjuvant therapy for early colon cancer: current status.Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer.Laparoscopic colectomy decreases the time to administration of chemotherapy compared with open colectomy.A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatment and surgery for rectal cancer.Antitumoral potential, antioxidant activity and carotenoid content of two Southern Italy tomato cultivars extracts: San Marzano and Corbarino.Abnormal expression of TRIB3 in colorectal cancer: a novel marker for prognosis.Rectal cancer: a reviewMACC1 expression levels as a novel prognostic marker for colorectal cancer.Improving decision-making in early breast cancer: who to treat and how?Usefulness of the preoperative administration of tegafur suppositories as alternative adjuvant chemotherapy for patients with resectable stage II or III colorectal cancer: a KODK4 multicenter randomized control trial.Geographic difference in safety and efficacy of systemicchemotherapy for advanced gastric or gastroesophagealcarcinoma: a meta-analysis and meta-regression.A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer.Association of common gene variants in the WNT/β-catenin pathway with colon cancer recurrence.
P2860
Q24240635-CB0D34E3-C46F-44A1-A857-83ECBAFA8F47Q24651467-8BD689D5-C458-40DD-848A-E9E37365B5EBQ26748744-E5BDA577-6505-43CB-8654-D160BE8A9B64Q28681140-19B8EDD4-5F9F-4F43-85E6-71EC9303C868Q30249616-9E188EF0-FCB7-4FAC-8D25-5767C646284DQ30316930-681F67CA-A22B-4CBC-BB70-1404F7A0EF2DQ30884763-6650A964-8CE3-4A90-97AD-678F1DA74F79Q33518321-8D31B8EC-DD2D-4AE7-B804-05B74942D89AQ33640779-5E585552-3E34-4B3C-A427-10A40C6337C3Q33947455-66A91B6C-CAB9-42B7-8919-BC4269F2F981Q34293104-3C7A3B32-6E4A-4AB0-AD6A-7DF3DC425077Q34368278-509E19E0-B22A-4457-AD10-3171CB46FFA5Q34632080-B04F913B-D820-4A66-A429-EEB102C3AF8CQ34974760-E2855AEE-5782-42D5-86E6-E74576800F80Q34984086-AC733409-BCAC-4A9D-B0DF-A95A6321FF39Q35183678-F8883AF3-82A1-478F-B4AE-37C836C7D7ECQ35583987-481D70B4-1C87-43DA-BB3F-05446F2B0D93Q35899039-C019AF44-6049-406D-8AAB-5BA8DB7F68C5Q36643640-62560492-818F-4B8E-8378-034454306739Q36689794-84F86710-C8F1-42F2-98C2-C2162396F49AQ36979735-C007D458-8B35-4A19-B113-C07A52BD1541Q37132721-AE9B0748-C1A1-4DC3-AA7B-63B5154AF1A6Q37149152-6CE50D4E-EFDA-48E5-80A2-0231C7450723Q37167151-BA6AE5A0-367E-4AF8-89A9-9176E15C4E5EQ37225720-B93B33BD-537B-466B-8B9A-04A3057AFA3EQ37468817-8A12B17A-E513-4B1F-A9B6-E442FB1FEABAQ37562465-9F9A215C-A5FB-4AF6-A8AA-0513D741F555Q37956401-A1C45C92-4F26-4D1E-B279-2EF3FB26258DQ38002127-F8CF2DC8-96AC-4054-9F57-0B286CD60B36Q38204291-02E47852-2BC5-4DE1-9E5C-2C96E4406F72Q38272671-B094A85C-2F77-458B-AE61-15022438D686Q38794677-648A9574-C556-43D6-8DCF-FDA7FFF8C9A3Q39776400-3EE62402-D752-42F6-B585-6FF0654421E1Q42555130-22C72B12-DBA9-4B0D-B029-768FBCD6C367Q42931083-B6D6D5D6-BF6C-435B-9205-306C0F3C2D1AQ43411303-7B00866B-0285-43AB-A171-4F4BB5330FE3Q44042470-B17C71FF-CA0F-42E4-91E2-E8A5AF30808CQ44734913-EB1BA16B-1245-4F4F-AEAD-7FD14610140DQ45945682-8740DD5B-6A80-43FE-BADA-75423E2250EEQ46014740-3B0583CD-9D7B-415B-B040-46008A42F6FB
P2860
Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Phase III study comparing a se ...... final results of GERCOR C96.1.
@en
Phase III study comparing a se ...... final results of GERCOR C96.1.
@nl
type
label
Phase III study comparing a se ...... final results of GERCOR C96.1.
@en
Phase III study comparing a se ...... final results of GERCOR C96.1.
@nl
prefLabel
Phase III study comparing a se ...... final results of GERCOR C96.1.
@en
Phase III study comparing a se ...... final results of GERCOR C96.1.
@nl
P2093
P356
P1476
Phase III study comparing a se ...... final results of GERCOR C96.1.
@en
P2093
Aimery de Gramont
Arnaud Boutan-Laroze
Christophe Louvet
Emmanuel Achille
Emmanuel Quinaux
Erik Gamelin
Gérard Lledo
Isabelle Debrix
Marc Buyse
Michel Flesch
P304
P356
10.1200/JCO.2007.12.2234
P407
P577
2007-08-01T00:00:00Z